Popular on s4story
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- Venardi Zurada LLP Offers Legal Support to Families After Deadly Lake Tahoe Boat Capsizing
- Jasmine Farrell Releases New LGBTQ+ Poetry Collection - Rising From the Roots
- K2 Integrity's U.S. and EMEA Teams Recognized in Chambers and Partners 2025 Guides
- Elevated Healing Treatment Centers: Redefining Mental Health Care with Compassionate, Evidence-Based, and Accessible Services
- Holiday Inn Express North Hollywood Burbank Area Announces Conversion to Hampton Inn North Hollywood
- ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team
- Lottery.com Inc. Secures $300 Million in Growth Capital, Confirms Nasdaq Compliance & Acquires UAE Sports Incubator Amid High-Profile Brand Exposure
- Anna D. Banks' Street Smart, Money Smart Hits #1 on Amazon Teen & Young Adult New Releases Chart
- Nationally Recognized Hispanic Activist and Businessman, Luis Figueroa, to speak at CPAC Latino 2025, Showcasing Hispanic Leadership in Action
Similar on s4story
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Adostics & Genmega Announce the Introduction of A-POD
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
Huma named for its successful and innovative approach to clinical trials in new UK government review USA - English USA - English
S For Story/10587415
- Huma's innovative approach to medical research cited in Lord James O'Shaughnessy's review for clinical trials improvement in the UK
- The review is part of a new widespread policy approach to ignite the UK's life sciences sector
- Innovating clinical trials using digital technologies such as Huma's platforms can make them more accessible, more diverse, faster to recruit and retain patients
NEW YORK and LONDON, May 25, 2023 /PRNewswire/ -- Huma Therapeutics ("Huma"), a leading global digital health company, is named today as an exemplar of innovation in medical research in an independent review led by former Health Minister, Lord James O'Shaughnessy entitled Commercial clinical trials in the UK.
The review was commissioned by the UK government to make recommendations to improve the clinical trials landscape in the UK. It proposes a range of 'significant actions' to bend the performance curve of trials dramatically, stating: 'The partnership between 2 very different UK life science success stories – AstraZeneca and Huma – shows the potential of the UK in this field'. The review includes a short case study of our joint work1.
The review proposes that the government doubles the numbers of people taking part in commercial clinical trials in the next two years, and doubles it again by 2027. One of its 27 recommendations is the support and promotion of decentralised clinical trials, which are enabled by digital technology. It calls on stakeholders to develop guidance for decentralised and innovative trials by the end of 2023 to keep pace internationally.
Decentralised clinical trials
An estimated 80% of clinical trials do not meet initial patient enrollment goals and timelines2. Decentralised trials can, says the review, increase public involvement in research and new therapies. Data can be collected from the comfort of participants' homes without disrupting their lives, reducing or eliminating the need to travel to clinical trial sites. Retention and adherence to trial protocols through an improved experience can lower the overall cost of research. Decentralised trials also hold the promise of increasing diversity so that new medicines benefit people from all ethnicities and backgrounds.
More on S For Story
- Emmy-Winning Journalist José Martínez Releases Debut Book Your English is Great, But…
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
Dan Vahdat, Founder & CEO of Huma, said: "As a UK-headquartered company we really want to play our role in supercharging bodies such as the NHS and helping the UK re-establish its leadership position in clinical research. We have the innovative platform and clinical trials expertise to do so: our technology has supported some of the world's largest clinical trials from Covid19 to the Our Future Health study aiming to carry out research on 5 million participants. We join Lord O'Shaughnessy's call for all stakeholders to come together with both a renewed ambition and innovative mindset to bend the performance curve of clinical trials in the UK."
Huma's digital technology platforms support decentralised trials through an easy to configure, end-to-end solution, without hard coding, which allows rapid setup for clinical study requirements. This features pre-built modules including eConsent, ePRO and eCOA that can be adapted to protocols enabling quick setup of therapeutic study requirements.
References:
- Commercial clinical trials in the UK: the Lord O'Shaughnessy review. Case study: AstraZeneca and Huma partnership
In March 2022, AstraZeneca, a global, science-led biopharmaceutical company headquartered in the UK, took a step towards harnessing this technology-driven, decentralised clinical trial opportunity through its partnership with Huma Therapeutics, a leading global digital health company also headquartered in the UK.
Huma's technology platform is founded on the first and only disease-agnostic software as a medical device (SaMD) to hold EU Medical Device Regulations (MDR) class IIb certification status. Its adaptations are used on a global scale by more than 1.8 million patients across around 3,000 hospitals and clinics and by more than 650,000 participants across research. Through Huma's primary care division, iPLATO Healthcare, whose digital service is used by 31 million people across the UK, digital technology is also driving recruitment into the UK's largest research programme, Our Future Health, through text messages and push notifications to invite people to join this incredible research programme.
More on S For Story- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Author Launches The Starlight Bond Website with Movie Licensing Proposal
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
Partnering with Huma enables AstraZeneca to conduct clinical trials in an entirely new way. For example, a global decentralised study of AstraZeneca's COVID-19 vaccine was designed to allow participants to report data on mobile phones across multiple continents, without ever visiting a trial site. In Germany, Huma and AstraZeneca worked together on a real-world evidence study to identify patients at risk of developing chronic kidney disease, resulting in the potential to recruit 7,000 patients in a single month.
These are powerful examples of a global pharma leader partnering with a British technology company to show the potential of digital-first care and research.
By combining digital technology with investigational research, AstraZeneca and Huma believe that this innovative approach will deliver marked improvements in the clinical trials space, ultimately resulting in the faster delivery of new and better medicines to patients in the UK and worldwide. - Johnson, O. (2015). An evidence-based approach to conducting clinical trial feasibility assessments. Clinical investigation, 5, 491-499.
About Huma
Huma Therapeutics is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.
Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8+ million active users in healthcare and 650,000+ participants across research. Huma's regulated Software as a Medical Device is the only platform to hold EU MDR Class IIb regulatory status. It powers:
- Digital first care for health systems
- companion apps to support patients through treatment and drug therapies
- virtual clinical trials to accelerate research
Please visit www.huma.com and follow us on LinkedIn at Huma
Media contact:
Karen Birmingham PhD
Head of PR & Communications, Huma
[email protected]
+44 (0) 7866 609314
Logo: https://mma.prnewswire.com/media/1427908/Huma_Logo.jpg
SOURCE HUMA Therapeutics
Filed Under: Business
0 Comments
Latest on S For Story
- Former Teacher to Dr. Phil's Critique: "Unschooling Isn't Chaos — It's the Future"
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Curtis Sergeant's Book The Only One Continues to Equip Christians to Live Fully in by and for God
- Emmy-Winning Journalist José Martínez to Debut Powerful New Book at New York Mobile Film Festival
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- Wordeee Publishes Casting Pros to Know: Reality TV Edition by Asjai Lou
- Digi 995 Audiobooks Officially Released: Fans Can Now Listen to the Complete Trilogy
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- New Children's Book Helps Kids and Parents Navigate Anxiety Together
- New TSA-Compliant Medication Packing Tool Helps Travelers Avoid Airport Delays and Customs Issues
- Wordeee Publishes Am I a Weed? by Margie Stiles
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- The Journey of BECOMING the Soul Alchemist — New Book by Kay Sanders Guides Readers to Deep Inner Transformation
- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)